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Abstract
Introduction: sarcopenia is associated with adverse health outcomes. The aim of this study was to describe the prevalence
of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older
People (EWGSOP) consensus deﬁnition.
Methods: we applied the EWGSOP deﬁnition to 103 community-dwelling men participating in the Hertfordshire
Sarcopenia Study (HSS) using both the lowest third of dual-energy X-ray absorptiometry (DXA) lean mass (LM) and the
lowest third of skin-fold-based fat-free mass (FFM) as markers of low muscle mass. We also used the FFM approach
among 765 male and 1,022 female participants in the Hertfordshire Cohort Study (HCS). Body size, physical performance
and self-reported health were compared in participants with and without sarcopenia.
Results: the prevalence of sarcopenia in HSS men (mean age 73 years) was 6.8% and 7.8% when using the lowest third of
DXA LM and FFM, respectively. DXA LM and FFM were highly correlated (0.91, P < 0.001). The prevalence of sarcope-
nia among the HCS men and women (mean age 67 years) was 4.6% and 7.9%, respectively. HSS and HCS participants
with sarcopenia were shorter, weighed less and had worse physical performance. HCS men and women with sarcopenia
had poorer self-reported general health and physical functioning scores.
Conclusions: this is one of the ﬁrst studies to describe the prevalence of sarcopenia in UK community-dwelling older
people. The EWGSOP consensus deﬁnition was of practical use for sarcopenia case ﬁnding. The next step is to use this
consensus deﬁnition in other ageing cohorts and among older people in a range of health-care settings.
Keywords: sarcopenia, prevalence, EWGSOP consensus definition, muscle mass, fat-free mass, grip strength, gait speed,
older people
Introduction
Sarcopenia, the loss of skeletal muscle mass and function
with age [1], is associated with disability, morbidity and
mortality [2–5]. Estimates for the total decline in the
muscle mass between the ages of 40 and 80 years range
from 30% to 50% [6, 7] and the annual decline in function-
al capacity is reported to be 1–2% after the age of 50
increasing to as much as 3% after the age of 60 [8].
Well-recognised lifecourse inﬂuences on muscle mass and
strength include age, gender, heritability, adult body size,
physical activity, nutrition and co-morbid disease [9–11]. In
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addition, there is consistent evidence for a relationship
between poor growth in early life and sarcopenia [12].
Estimates of the prevalence of sarcopenia in older men
and women worldwide vary from 3% to 30% according to
the operational deﬁnition implemented [8, 13–17]. There
has recently been progress in the ﬁeld with convergence in
the approaches used to deﬁne sarcopenia. The European
Working Group on Sarcopenia in Older People (EWGSOP)
[1] has published a consensus deﬁnition based on the ascer-
tainment of lean mass (LM), grip strength and gait speed
that provides a clear, structured and understandable
method for sarcopenia case ﬁnding (See Figure 1 and
supplementary data available in Age and Ageing online). The
guidelines recommend the measurement of muscle mass by
dual-energy X-ray absorptiometry (DXA), bioelectrical im-
pedance (BIA), computerised tomography (CT), magnetic
resonance imaging (MRI) or simple anthropometry; choice
depending on local availability. Handheld dynamometry is
recommended for the measurement of muscle strength and
gait speed to characterise physical performance. The
EWGSOP also conceptualised a grading for sarcopenia
such that those with pre-sarcopenia have a decrease in
muscle mass without disturbance in strength or function,
those with sarcopenia have decreased mass and strength or
function, and those with severe sarcopenia have decreased
mass, strength and function [1].
Previous cross-sectional studies in North America and
Europe have described a sarcopenia index (muscle mass/
height2) and used a cut-off that is two standard deviations
(SD) or more lower than a mean derived from a healthy
young reference sample [1, 18]. This approach has been
endorsed by the EWGSOP but its application requires refer-
ence values from relevant young, healthy, gender and
ethnicity-matched populations; data that may not always be
available in all settings. Pragmatic approaches to the identiﬁca-
tion of sarcopenia, which do not rely on resource intensive
scanning or scarce reference data are required to characterise
the burden of sarcopenia in a wide range of populations. For
example, one US study used an index of fat-free mass (FFM)
as well as the lowest third of FFM as approaches to deﬁne sar-
copenia [14]. In the present study, we evaluate an anthropo-
metric estimation of LM and use it in the EWGSOP
deﬁnition of sarcopenia to determine the prevalence of sarco-
penia in a UK population of community-dwelling older men
and women from the Hertfordshire Cohort Study (HCS).
Methods
The HCS has been described in detail previously [19]. The
current study utilises two samples of community-dwelling
HCS participants. First, 103 men, average age 73 years,
who participated in the Hertfordshire Sarcopenia Study
(HSS) substudy of HCS who had detailed data collected on
anthropometry, DXA, grip strength and physical perform-
ance measures [20]. Secondly, 765 men and 1,022 women
mean age 67 years, who participated in HCS who had an-
thropometry, grip strength and physical performance
measures, but not DXA (HCS PP). Ethical approval was
obtained from the Hertfordshire Research Ethics
Committee. All participants gave written informed consent.
Measurements
Body composition in the HSS was assessed by DXA
(Hologic Discovery, software version 12.5) and multisite
skin-fold thickness (SFT) measurement. In the HCS PP
sample, body composition was assessed by SFT only [21].
Weight was measured once to the nearest 0.1 kg with ﬂoor
scales (SECA, Hamburg, Germany). Height was measured
to the nearest 0.1 cm. Physical performance was assessed
by a battery comprising chair rises, a timed 6-m up and go
test (TUG) and a 3-m customary paced walk; used to
calculate walking speed in metres per second (m/s) [22].
A walking speed of ≤0.8 m/s identiﬁed subjects with
poorer physical performance [1]. A standardised protocol
[23] was used to measure isometric grip strength with a
Jamar dynamometer (Promedics, Blackburn, UK). Low
muscle strength was classiﬁed as grip strength <20 kg in
women and <30 kg in men [1]. All participants completed
the SF-36 health-related quality of life (HRQoL) question-
naire at both HCS baseline and HSS follow-up from which
self-reported general health (GH) and physical functioning
(PF) domain scores were derived.
Statistical analysis
Percentage body fat was derived from the average SFT [24].
Fat mass was derived by multiplying body weight by per-
centage body fat. FFM, a proxy for lean muscle mass, was
estimated by subtracting fat mass from body weight [24].
The maximum values of six grip measures were used.
Variables were summarised using means and SD or
medians and inter-quartile ranges (IQRs) for continuously
distributed variables. Pearson’s correlation coefﬁcient was
used to describe the relationship between skin-fold-
based FFM and DXA LM in the HSS sample. In the
absence of young reference values for DXA-derived LM or
reliable FFM cut-off points, the bottom thirds of the sex-
speciﬁc distributions of DXA LM or skin-fold-based FFM
were used to identify participants with low LM. The
EWGSOP algorithm was then used to estimate the preva-
lence of sarcopenia in both study samples using DXA LM
or skin-fold-based FFM as available. Body composition,
physical performance and SF-36 domain scores were con-
trasted between individuals with and without sarcopenia
using ANOVA, t-tests, Kruskal–Wallis and Wilcoxon tests
as appropriate. All analyses were carried out for men and
women separately using STATA, release 11 (Stata Corp,
College Station, TX, USA).
Results
Summary characteristics of the HSS and the HCS PP
samples of men and women are presented in Table 1. The
implementation of the EWGSOP algorithm among HSS
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men revealed a prevalence of sarcopenia of 6.8% when the
lowest third of the distribution of DXA LM was used as
the marker of the low muscle mass and of 7.8% when the
lowest third of the distribution of skin-fold-based FFM was
used (See Figures 2a, b, Table A1 and supplementary data
available in Age and Ageing online). The high correlation
(r = 0.91, P < 0.001) between DXA LM and skin-fold-
based FFM justiﬁed the use of skin-fold-based FFM as a
marker of muscle mass.
The implementation of the EWGSOP algorithm for men
and women in the HCS PP sample using the sex-speciﬁc
lowest third of the distribution of skin-fold-based FFM as a
marker of low muscle mass revealed a prevalence of
sarcopenia of 4.6% among men and 7.9% among women
(See Figures 3, 4, Table A1 and supplementary data available
in Age and Ageing online). The prevalence of the extended
deﬁnition of sarcopenia among HSS men and HCS PP men
and women is also presented in Table A1 available as supple-
mentary data in Age and Ageing online.
HSS men with sarcopenia were on average older,
shorter, weighed less, had lower mid-thigh circumferences,
and as expected recorded slower TUG times than men
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Anthropometry and functional characteristics of HSS men according to EWGSOP sarcopenia status
HSS men
No sarcopenia (n= 96), mean (SD) Sarcopenia (n= 7), mean (SD) P-value* P-value**
Age (years) 72.4 (2.4) 74.4 (2.9) 0.04 0.02
Height (cm) 174.9 (6.3) 165.8 (5.6) <0.001 <0.001
Weight (kg) 83.6 (12.5) 70.1 (7.2) 0.006 0.01
BMI (kg/m2) 27.3 (3.6) 25.5 (1.6) 0.20 0.27
Waist circumference (cm) 102.2 (10.4) 95.6 (8.9) 0.11 0.11
Hip circumference (cm) 105.5 (6.9) 100.0 (4.0) 0.09 0.07
Mid-thigh circumference (cm) 52.0 (4.2) 48.1 (2.8) 0.02 0.02
Physical performance
TUG (s) 10.5 (1.8) 12.5 (4.3) 0.01 0.05
Chair rise time (s) 17.1 (4.2) 18.7 (4.2) 0.37 0.79
Self-report Median (IQR) Median (IQR) P-value*** P-value****
SF-36 General health 77 (72–87) 67 (57–82) 0.21 0.31
SF-36 Physical functioning 95 (90–100) 95 (70–100) 0.21 0.19
DXA, dual-energy X-ray absorptiometry; anthro, anthropometry; TUG, 6-m timed up and go.
*P-value for differences between those without sarcopenia (no sarcopenia + pre-sarcopenia, n= 96) and those with sarcopenia (sarcopenia + severe sarcopenia,
n= 7) described by DXA lean mass.
**P-value for differences between those without sarcopenia (n= 95) and those with sarcopenia (n= 8) described by FFM.
***P-value for the Wilcoxon two-sample test between those without sarcopenia (n= 96) and those with sarcopenia (n= 7) described by DXA lean mass.
****P-value for the Wilcoxon two-sample test between those without sarcopenia (n= 95) and those with sarcopenia (n= 8) described by FFM.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Characteristics of HSS and HCS PP participants
HSS men (n= 103) HCS PP men (n= 765) HCS PP women (n= 1022)
n Mean (SD) n Mean (SD) n Mean (SD)
Age (years) 103 72.5 (2.5) 765 67.0 (2.6) 1022 67.1 (2.6)
Height (cm) 103 174.3 (6.7) 765 174.1 (6.4) 1022 160.8 (5.8)
Weight (kg) 103 82.7 (12.6) 765 82.7 (13.1) 1022 71.5 (13.2)
BMI (kg/m2) 103 27.2 (3.5) 765 27.2 (3.8) 1022 27.7 (4.9)
Lean mass DXA 103 56.4 (6.7) — — — —
Fat % DXA 103 26.8 (4.9) — — — —
Fat mass (kg) DXA 103 22.2 (6.5) — –– — —
Body fat % anthro 103 26.9 (5.0) 765 28.4 (5.2) 1022 39.7 (4.9)
Fat-free mass (kg) anthro 103 60.0 (7.2) 765 58.8 (7.2) 1022 42.7 (5.9)
Waist circumference (cm) 103 101.7 (10.4) 764 100.9 (10.5) 1018 92.4 (12.4)
Hip circumference (cm) 103 105.2 (6.8) 765 103.9 (7.2) 1021 107.9 (10.7)
Mid-thigh circumference (cm) 103 51.7 (4.2) 762 52.2 (4.3) 1013 53.3 (5.8)
Physical performance
Grip strength (kg) 103 38.7 (8.3) 765 43.9 (7.6) 1022 26.3 (5.8)
TUG (s) 103 10.6 (2.1) 765 10.8 (2.7) 1022 11.1 (3.0)
Chair rise time (s) 103 17.2 (4.2) 333 15.5 (3.4) 642 18.5 (5.3)
Walking speed (m/s) 103 1.1 (0.2) 765 0.9 (0.1) 1022 0.9 (0.2)
SF-36 domain score Median (IQR) Median (IQR) Median (IQR)
General health 103 77 (72–87) 764 72 (62–82) 1022 72 (62–87)
Physical functioning 103 95 (90–100) 764 90 (80–95) 1022 85 (65–95)
DXA, dual-energy X-ray absorptiometry; anthro, anthropometry; TUG, 6-m timed up and go.
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without sarcopenia, although analyses were limited by the
small sample size. Results were consistent between the
DXA LM and skin-fold FFM implementations of
the EWGSOP deﬁnition (Table 2).
Both HCS PP men and women with sarcopenia were
on average shorter, weighed less, had lower waist, hip and
mid-thigh circumferences, and also recorded slower TUG
and chair rise test times than their counterparts without
sarcopenia (Table 3). HCS PP men and women with sarco-
penia also reported poorer (i.e. lower) SF-36 GH and PF
scores (Table 3).
Discussion
In this present study, we describe the prevalence of sarco-
penia among community-dwelling older people in the UK
using the EWGSOP recommended diagnostic algorithm.
Among 103 community-dwelling older men who partici-
pated in the HSS, the prevalence of sarcopenia was 6.8%
when the lowest third of DXA LM was used as a marker
of low muscle mass and was 7.8% when the lowest third of
skin-fold-based FFM was used. Using the lowest third of
skin-fold-based FFM to denote low muscle mass, the
prevalence of sarcopenia among community-dwelling older
men (n = 765) and women (n = 1022) of the HCS PP
group was 4.6% and 7.9%, respectively.
Our results suggest that the EWGSOP algorithm is useful
to deﬁne cases with and without sarcopenia. Furthermore,
the algorithm can be implemented in the absence of reference
values for muscle mass by using muscle mass thirds as we
have shown. This model can easily be applied to muscle mea-
surements obtained from DXA, BIA, CTor MRI.
Studies of the prevalence of sarcopenia in North America
have primarily used muscle mass derived from DXA or BIA
as a skeletal muscle mass index and deﬁned sarcopenia as two
SDs below the mean for relevant young healthy reference
populations. For example, in 883 participants of the New
Mexico Elder Study, prevalence increased from 13% to 24%
in people under 70 years of age to >50% in persons over 80
years and differed by ethnicity [13]. In a US cross-sectional
survey by Melton et al., [16] age- and sex-adjusted prevalence
rates varied from 6% to 15% in participants who were 65
years or older and depended on the muscle parameter used to
deﬁne sarcopenia. This was similar to ﬁndings from a study
of 237 men and women aged 64–92 years by Iannuzzi-Sucich
et al. [25] where the prevalence was reported to be 27% in
men and 23% in women and increased in those over 80 years
to 53% and 31%, respectively. There are also some European
studies. For example, in a sample of Spanish community-
dwelling older people, prevalence rates were reported to be
10% in men (mean age: 74.6) and 33% in women (mean age:
75.3 years) [8] and in a French population aged 60–78 years,
the reported prevalence was 3.6% in men and 2.8% in
women [17]. In the Leiden Longevity Study by Bijlsma et al.
[26], the prevalence of sarcopenia was 4.6% in men and 2.1%
in women.
Other investigators have used anthropometry to charac-
terise muscle mass. For example, Landi et al. [27] used
thirds of mid-arm muscle circumference (MAMC) as a
marker of muscle mass in the absence of a reference
population. Physical performance and function including
handgrip improved signiﬁcantly as MAMC increased.
Furthermore, those in the highest third of MAMC had a
lower risk of death. FFM has also been used to deﬁne
sarcopenia in previous studies. For example, in a study of
1700 community-dwelling older adults by Castillo et al. [14],
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. Anthropometry and functional characteristics of HCS PP men and women according to EWGSOP sarcopenia
status
HCS men HCS women
No sarcopenia (n= 730) Sarcopenia (n= 35) No sarcopenia (n= 941) Sarcopenia (n= 81)
Mean (SD) Mean (SD) P-value* Mean (SD) Mean (SD) P-value*
Age (yrs) 67.0 (2.6) 67.4 (2.6) 0.400 67.1 (2.6) 67.5 (2.7) 0.140
Height (cm) 174.5 (6.1) 166.1 (6.1) <0.001 161.2 (5.7) 155.8 (4.9) <0.001
Weight (kg) 83.4 (12.9) 68.2 (9.5) <0.001 72.6 (13.1) 58.9 (6.5) <0.001
BMI (kg/m2) 27.4 (3.8) 24.7 (3.5) <0.001 27.9 (4.9) 24.3 (3.1) <0.001
Waist circumference (cm) 101.2 (10.5) 93.9 (9.2) <0.001 93.1 (12.4) 83.5 (7.7) <0.001
Hip circumference (cm) 104.2 (7.1) 97.5 (5.9) <0.001 108.6 (10.7) 99.5 (6.6) <0.001
Mid-thigh circumference (cm) 52.4 (4.2) 48.2 (4.1) <0.001 53.6 (5.8) 49.7 (5.2) <0.001
Physical performance
TUG (s) 10.6 (2.0) 13.8 (8.3) <0.001 10.9 (2.5) 12.7 (5.7) <0.001
Chair rise time (s) 15.4 (3.4) 19.1 (3.2) <0.001 18.3 (5.2) 20.6 (6.2) 0.002
Self-report Median (IQR) Median (IQR) P-value** Median (IQR) Median (IQR) P-value**
SF-36 General health 72 (62–85) 60 (45–77) <0.001 75 (62–87) 67 (57–77) <0.001
SF-36 Physical functioning 90 (80–95) 85 (55–90) <0.001 85 (65–95) 75 (55–90) 0.002
DXA, dual-energy X-ray absorptiometry; anthro, anthropometry; TUG, 6-m timed up and go.
*P-value for differences between those without sarcopenia (no sarcopenia + pre-sarcopenia) and those with sarcopenia (sarcopenia + severe sarcopenia).
**P-value for the Wilcoxon two-sample test between those without sarcopenia and those with sarcopenia.
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FFM was deﬁned both as an index and as the lowest third
of FFM. The prevalence of sarcopenia, when deﬁned as an
index, was 1.9% in men and 2.5% in women aged 60–69
years, but increased to 16% and 13%, respectively, over the
age of 80 years. Men and women with sarcopenia had
reduced FFM, fat mass and grip strength compared with
those without sarcopenia. We agree with the observation
made by Castillo et al. [14] that using thirds to investigate
sarcopenia as well as other classiﬁcations is useful when
appropriate reference groups are unavailable.
In the current study, we assessed whether sarcopenia identi-
ﬁed by the EWGSOP deﬁnition had an impact on HRQoL
and have shown that HCS PP men and women with sarcope-
nia had poorer self-reported GH and PF scores. This is con-
sistent with a previous study where we found that grip strength
was associated with HRQoL [28]. A recent study which com-
pared HRQoL in those diagnosed with ‘sarco-osteopenia’ with
HRQoL in healthy subjects, showed lower scores in the role-
physical, vitality and role-emotional domains consistent with
sarcopenia impacting adversely on HRQoL [29].
The prevalence of sarcopenia will clearly vary according
to which diagnostic criteria are applied to different study
samples. This is evident in studies that have deﬁned sarcope-
nia as a skeletal muscle mass index and in those that have
used anthropometry as a marker of muscle mass [14, 18, 26].
A few consensus operational deﬁnitions of sarcopenia have
been developed based on low muscle mass and gait speed
[18, 30], but these have invariably relied on comparison with
healthy young reference values. In spite of methodological
differences, the prevalence of sarcopenia in our study is
broadly comparable with that from similar studies in the lit-
erature [14, 26, 31]. The EWGSOP consensus deﬁnition
relies on ascertainment of gait speed and muscle mass by
any means available and we believe that the algorithm is of
practical use especially when a reference sample with which
to compare muscle mass is unavailable. The EWGSOP deﬁ-
nitions, usefully, also identify those with, and who are at risk
of sarcopenia. This permits the use of targeted intervention
strategies to minimise risk of adverse health outcomes as a
consequence of the later development of sarcopenia.
This study has a number of potential limitations. As dis-
cussed by Bijlsma et al. [26] although gait speed represents
muscle function it is dependent on intact cognition, neural
control and joint control; therefore, the algorithm may not
be practical in older patients who are unable to mobilise efﬁ-
ciently. In this setting, a single measure of muscle function
such as grip strength may be better to ascertain whether a
patient has sarcopenia. This clearly requires further research.
A relatively small sample size in the HSS as well as a healthy
participant effect in HSS and HCS may have underestimated
the prevalence of sarcopenia in the current study. The use of
FFM as a marker of low muscle mass could be questioned
but we suggest this is a pragmatic implementation of the
EWGSOP criteria in the absence of availability of other
measures of muscle mass in the HCS PP sample. Moreover,
we have shown that skin-fold-based FFM and DXA LM
were highly correlated among HSS men and led to similar
sarcopenia classiﬁcation. We acknowledge that the same mag-
nitude of correlation between skin-fold-based FFM and
DXA LM may not be evident in women; this requires
further investigation. Finally, the HCS PP participants repre-
sent the young–old end of the spectrum of older people.
Future follow-up studies of the HCS cohort could yield
useful data on sarcopenia prevalence as well as functional
and mortality data in the oldest old.
Previous studies have used height-adjusted lean and
FFM in their deﬁnitions of sarcopenia; it is unclear
whether this markedly affects those who are identiﬁed as
having sarcopenia or the overall prevalence of sarcopenia.
Furthermore, the EWGSOP guidelines do not explicitly ad-
vocate application of height-adjusted values in the
EWGSOP algorithm [1]. We have implemented a simple
unadjusted form of the EWGSOP algorithm which could
be applied in a range of health-care settings where the reli-
able ascertainment of height may not be possible; however,
we acknowledge that other approaches are clearly possible.
This study also has a number of strengths. First, the study
was conducted on a large sample of well-characterised
community-dwelling older men and women living in a
deﬁned geographical area. Secondly, as far as we are aware our
study is one of the ﬁrst to describe the prevalence of sarcope-
nia in the UK using the EWGSOP criteria. Thirdly, the HCS
participants have been compared with those in the nationally
representative Health Survey for England and have been
found to be broadly comparable in terms of their health and
lifestyle [19]. We, therefore, suggest that the results from the
current study could be reasonably generalised to the wider
population of older men and women in England.
In conclusion, it is time to act. Sarcopenia is associated
with multiple adverse outcomes and there is an increased
need for its recognition in clinical practice as well as in
research. Several consensus deﬁnitions exist. We found
the EWGSOP consensus deﬁnition of practical use in iden-
tifying the prevalence of sarcopenia among community-
dwelling older people in the UK. We suggest that the FFM
approach can be used to implement the EWGSOP algo-
rithm in the absence of DXA LM data. The next step is to
deﬁne sarcopenia in other ageing cohorts as well as among
older people in a range of health-care settings.
Key points
• Sarcopenia is associated with multiple adverse outcomes.
• The EWGSOP consensus deﬁnition provides a practical
means of identifying sarcopenia in community-dwelling
older people.
• Sarcopenia now needs to be deﬁned in other ageing
cohorts as well as among older people in a range of
health-care settings.
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Supplementary data mentioned in the text are available to
subscribers in Age and Ageing online.
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